ThromboGenics’ JETREA® Available In Germany Public And Private Market

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has launched JETREA(R) in Germany, the second European market where the product is now available...

Full Story →